✦ LIBER ✦

624 Are there differences in baseline characteristics or treatment outcomes with peginterferon α-2a (40 kDa) and ribavirin in patients infected with HCV genotype 1A versus 1B?

Book ID: 117374130
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 121 KB
Volume: 42
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(05)82035-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

592 Are changes in lymphocytes during pe

592 Are changes in lymphocytes during peginterferon α-2a (40 kDa) and ribavirin treatment in patients with co-infection related to HCV response? Findings from apricot

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 115 KB

619 Peginterferon α-2a (40 kDa) plus rib

619 Peginterferon α-2a (40 kDa) plus ribavirin in treatment-naive patients with chronic hepatitis C and genotype 2 or 3 infection: Individual estimated probability of sustained virological response

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 252 KB

PGI2 IS THERE ANY DIFFERENCE BETWEEN THE

PGI2 IS THERE ANY DIFFERENCE BETWEEN THE EFFECTS OF THERAPY WITH PEGINTERFERON-ALPHA-2A VERSUS STANDARD-DOSE PEGINTERFERON-ALPHA-2B? A META-ANALYSIS COMPARING BOTH TREATMENTS PLUS RIBAVIRIN IN GENOTYPE 1/4 CHRONIC HEPATITIS C VIRUS (HCV) INFECTION PATIENTS

✍ FMR Barros; H Cheinquer; LG Borges; E Santos 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB

Predicting treatment outcome following 2

Predicting treatment outcome following 24 weeks peginterferon α-2a/ribavirin therapy in patients infected with HCV genotype 1: Utility of HCV-RNA at day 0, day 22, day 29, and week 6

✍ Esther Lukasiewicz; Kristoffer Hellstrand; Johan Westin; Carlo Ferrari; Avidan U 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB

We sought to validate FIB-4 using data retrospectively collected from treatment-naive HIV/HCV patients. The original model was adapted in order to use AST and ALT levels expressed as times the upper limit of normality (ϫULN), as follows: (age [yr] ϫ AST [ϫULN]) ϫ 10/((PLT [10 9 /l]) ϫ (ALT [ϫULN]) 1

P.241 Treatment outcomes in patients wit

P.241 Treatment outcomes in patients with hepatitis C virus genotype 1a and 1b and persistently ‘normal’ alanine aminotransferase (ALT) levels receiving peginterferon alpha-2a (40KD) plus ribavirin

✍ S. Zeuzem; P. Marcellin; P. Pockros; N. Gitlin; P. Farci; M. Shiffman; J. Zarski 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 145 KB

The results of a randomized trial lookin

The results of a randomized trial looking at 24 weeks vs 48 weeks of treatment with peginterferon α-2a (40 kDa) and ribavirin combination therapy in patients with chronic hepatitis C genotype 1

✍ C. Brandão; A. Barone; F. Carrilho; A. Silva; M. Patelli; C. Caramori; R. Focacc 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 160 KB